Botulinum Toxin-A Injections Into Neurogenic Overactive Bladder-To Include or Exclude the Trigone? A Prospective, Randomized, Controlled Trial

被引:58
作者
Abdel-Meguid, Taha A. [1 ,2 ]
机构
[1] King Abdulaziz Univ Med City, Dept Urol, Jeddah, Saudi Arabia
[2] Menia Univ, Dept Urol, El Minia, Egypt
关键词
urinary bladder; neurogenic; spinal cord injuries; botulinum toxin type A; urinary incontinence; urodynamics; IDIOPATHIC DETRUSOR OVERACTIVITY; INTRADETRUSOR INJECTIONS; INCONTINENCE; STANDARDIZATION; TERMINOLOGY;
D O I
10.1016/j.juro.2010.08.028
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The short-term outcomes of initial detrusor injections vs combined detrusor-trigone botulinum toxin-A injections were determined in patients with spinal cord injury-neurogenic detrusor overactivity. Materials and Methods: Adults with refractory spinal cord injury-neurogenic detrusor overactivity who strictly discontinued anticholinergics were recruited for the study. At a 1: 1 ratio patients randomly received 300 U botulinum toxin-A intradetrusor injections excluding the trigone (detrusor arm) or 200 U intradetrusor plus 100 U intratrigonal injections (combined arm). Study end points were determination of the impact on incontinence episodes, complete dryness, quality of life, reusing anticholinergics, maximum detrusor pressure, reflex volume, maximum cystometric capacity, vesicoureteral reflux and adverse events. Patients were evaluated at baseline, and 2, 8, 12 and 18 weeks after injection. Statistical significance was considered at p<0.05. Results: Analysis included 18 patients per arm with no significant baseline differences. On within group analysis all parameters improved significantly compared to baseline. On between group analysis in the detrusor vs the combined arm at week 8 incontinence decreased by 52.4% vs 80.9% (number needed to treat 1.91 vs 1.23 patients, p<0.001), complete dryness was achieved in 33.3% vs 66.7% of patients (number needed to treat 3 vs 1.5, p<0.001) and quality of life score was decreased by 46.76% vs 48.13% (number needed to treat 2.14 vs 2.08, p<0.44). The absolute difference was 60% vs 82.5% for reflex volume (p<0.001), 66.2% vs 68.4% for maximum cystometric capacity (p<0.22) and -42.3% vs -41.9% for maximum detrusor pressure (p<0.21). At week 18 anticholinergics were needed again in 9 (50%) and 4 patients (22.2%) patients, respectively. No patient showed new or upgraded vesicoureteral reflux or reported significant adverse events. Conclusions: In the short term all parameters improved significantly in each arm. The superiority of including rather than excluding the trigone was significant.
引用
收藏
页码:2423 / 2428
页数:6
相关论文
共 45 条
  • [1] Botulinum toxin-A (Botox®) intradetrusor injections in children with neurogenic detrusor overactivity/neurogenic overactive bladder: A systematic literature review
    Game, Xavier
    Mouracade, Pascal
    Chartier-Kastler, Emmanuel
    Viehweger, Elke
    Moog, Raphael
    Amarenco, Gerard
    Denys, Pierre
    De Seze, Marianne
    Haab, Francois
    Karsenty, Gilles
    Kerdraon, Jacques
    Perrouin-Verbe, Brigitte
    Ruffion, Alain
    Soler, Jean-Marc
    Saussine, Christian
    JOURNAL OF PEDIATRIC UROLOGY, 2009, 5 (03) : 156 - 164
  • [2] Botulinum toxin A (Botox®) intradetrusor injections in adults with neurogenic detrusor overactivity/neurogenic overactive bladder:: A systematic literature review
    Karsenty, Gilles
    Denys, Pierre
    Amarenco, Gerard
    De Seze, Marianne
    Game, Xavier
    Haab, Francois
    Kerdraon, Jacques
    Perrouin-Verbe, Brigitte
    Ruffion, Alain
    Saussine, Christian
    Soler, Jean-Marc
    Schurch, Brigitte
    Chartier-Kastler, Emmanuel
    EUROPEAN UROLOGY, 2008, 53 (02) : 275 - 287
  • [3] Botulinum toxin type A injections into the trigone to treat idiopathic overactive bladder do not induce vesicoureteral reflux
    Karsenty, Gilles
    Elzayat, Ehab
    Delapparent, Thomas
    St-Denis, Benoit
    Lemieux, Marie-Claude
    Corcos, Jacques
    JOURNAL OF UROLOGY, 2007, 177 (03) : 1011 - 1014
  • [4] Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder
    Bentaleb, Y.
    Castel-Lacanal, E.
    Sallusto, F.
    De Boissezon, X.
    Malavaud, B.
    Marque, P.
    Rischmann, P.
    Game, X.
    PROGRES EN UROLOGIE, 2008, 18 (07): : 449 - 455
  • [5] Botulinum Toxin-A Injections for Idiopathic Overactive Bladder: A Systematic Review and Meta-Analysis
    Cui, Yu
    Wang, Long
    Liu, Longfei
    Zeng, Feng
    Niu, Jiping
    Qi, Lin
    Chen, Hequn
    UROLOGIA INTERNATIONALIS, 2013, 91 (04) : 429 - 438
  • [6] Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder
    Flynn, Michael K.
    Amundsen, Cindy L.
    Perevich, MaryAnn
    Liu, Fan
    Webstert, George D.
    JOURNAL OF UROLOGY, 2009, 181 (06) : 2608 - 2615
  • [7] Efficacy and Safety of Botulinum Toxin A Intradetrusor Injections in Adults with Neurogenic Detrusor Overactivity/Neurogenic Overactive Bladder: A Systematic Review
    Soljanik, Irina
    DRUGS, 2013, 73 (10) : 1055 - 1066
  • [8] Bacterial ecology and resistance to antibiotics in patients with neurogenic overactive bladder treated with intravesical botulinum toxin injections
    Levy, J.
    Le Breton, F.
    Jousse, M.
    Haddad, R.
    Verollet, D.
    Guinet-Lacoste, A.
    Amarenco, G.
    PROGRES EN UROLOGIE, 2014, 24 (12): : 744 - 749
  • [9] Evaluating the Efficacy and Safety of Botulinum Toxin in Treating Overactive Bladder in the Elderly: A Meta-Analysis with Trial Sequential Analysis of Randomized Controlled Trials
    Chen, Yu-Hsuan
    Kuo, Jen-Hao
    Huang, Yen-Ta
    Lai, Pei-Chun
    Ou, Yin-Chien
    Lin, Yu-Ching
    TOXINS, 2024, 16 (11)
  • [10] Hengli(R) Chinese Botulinum Toxin Type A for Treatment of Patients With Overactive Bladder: A Multicenter, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial
    Liao, Limin
    Liu, Qinggang
    Cong, Huiling
    Xu, Zhihui
    Li, Enhui
    Weng, Zhiliang
    Jiang, Haihong
    Liu, Ben
    Huang, Xiao
    Xia, Shujie
    Wen, Wei
    Wu, Juan
    Shi, Guowei
    Wang, Yang
    Li, Peijun
    Yu, Yang
    Fang, Zujun
    Zheng, Jie
    Tian, Ye
    Shang, Donghao
    Li, Hanzhong
    Huang, Zhongming
    Zhou, Liqun
    Xiao, Yunxiang
    Zhang, Yaoguang
    Wang, Jianlong
    Zhang, Xiaodong
    Zhang, Peng
    Wang, Dongwen
    Zhang, Xuhui
    Xie, Keji
    Wang, Bin
    Ma, Lulin
    Tian, Xiaojun
    Chen, Lijun
    Dong, Jinkai
    FRONTIERS IN PHARMACOLOGY, 2022, 13